Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial

Daniel S. Green, Franklin Ning, Anna Duemler, Timothy G. Myers, Kathryn Trewhitt, Irene Ekwede, Ann McCoy, Nicole Houston, Jung Min Lee, Stanley Lipkowitz, Alexandra Zimmer, Miroslava Pavelova, Erin N. Villanueva, Leslie Smith, Andrew Blakely, Yovanni Casablanca, Steven L. Highfill, David F. Stroncek, Naoza Collins-Johnson, Sandhya PanchJo Lynn Procter, Chauha Pham, Soumya Korrapati, Steven M. Holland, Lindsey B. Rosen, Ana T. Nunes, Kathryn C. Zoon, Christopher B. Cole, Christina M. Annunziata*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Purpose: Ovarian cancer is the most lethal gynecologic cancer and intrinsically resistant to checkpoint immunotherapies. We sought to augment innate immunity, building on previous work with IFNs and monocytes. Patients and Methods: Preclinical experiments were designed to define the mechanisms of cancer cell death mediated by the combination of IFNs a and g with monocytes. We translated these preclinical findings into a phase I trial of autologous IFN-activated monocytes administered intraperitoneally to platinum-resistant or -refractory ovarian cancer patients. Results: IFN-treated monocytes induced caspase 8-dependent apoptosis by the proapoptotic TRAIL and mediated by the death receptors 4 and 5 (DR4 and DR5, respectively) on cancer cells. Therapy was well tolerated with evidence of clinical activity, as 2 of 9 evaluable patients had a partial response by RECIST criteria, and 1 additional patient had a CA-125 response. Upregulation of monocyte- produced TRAIL and cytokines was confirmed in peripheral blood. Long-term responders had alterations in innate and adaptive immune compartments. Conclusions: Given the mechanism of cancer cell death, and the acceptable tolerability of the clinical regimen, this platform presents a possibility for future combination therapies to augment anticancer immunity.

Original languageEnglish
Pages (from-to)349-363
Number of pages15
JournalClinical Cancer Research
Volume29
Issue number2
DOIs
StatePublished - 15 Jan 2023
Externally publishedYes

Fingerprint

Dive into the research topics of 'Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial'. Together they form a unique fingerprint.

Cite this